Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19006261rdf:typepubmed:Citationlld:pubmed
pubmed-article:19006261lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19006261lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:19006261lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:19006261lifeskim:mentionsumls-concept:C0328767lld:lifeskim
pubmed-article:19006261lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:19006261lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:19006261lifeskim:mentionsumls-concept:C1414449lld:lifeskim
pubmed-article:19006261lifeskim:mentionsumls-concept:C1414450lld:lifeskim
pubmed-article:19006261lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:19006261pubmed:dateCreated2008-11-13lld:pubmed
pubmed-article:19006261pubmed:abstractTextThe prostate cancer HERV-K gag-related NGO-Pr-54 antigen was identified by SEREX analysis using autologous patient serum. NGO-Pr-54 mRNA was observed to be faintly expressed in normal prostate and strongly expressed in a variety of cancers, including ovarian cancer (5/8), prostate cancer (6/9), and leukemia (5/14). A phage plaque assay showed that a strong reaction was constantly observed with clone ZH042 in which the 5' end of NGO-Pr-54 is deleted, suggesting that it contained the sequence coding for the protein product. A TI-35 mAb was produced using a recombinant protein (438 aa) deduced from the sequence of ZH042. Transfection of clone ZH042 into 293T cells resulted in the production of an approximately 50-kDa molecule visualized by Western blotting. Natural production of the molecule was confirmed in a SK-MEL-23 melanoma cell line. An indirect immunofluorescence assay showed that NGO-Pr-54 protein was expressed on the cell surface as well as in the cytoplasm. Cell surface expression was confirmed by flow cytometry using the TI-35 mAb. The antibody response against NGO-Pr-54 was observed in patients with bladder (5.1%), liver (4.1%), lung (3.4%), ovarian (5.6%), and prostate (4.2%) cancer, as well as with malignant melanoma (13.2%).lld:pubmed
pubmed-article:19006261pubmed:languageenglld:pubmed
pubmed-article:19006261pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19006261pubmed:citationSubsetIMlld:pubmed
pubmed-article:19006261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19006261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19006261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19006261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19006261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19006261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19006261pubmed:statusMEDLINElld:pubmed
pubmed-article:19006261pubmed:issn1424-9634lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:YamashitaTosh...lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:UenakaAkikoAlld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:NakayamaEiich...lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:OldLloyd JLJlld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:ObataYuichiYlld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:SaikaTakashiTlld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:MorishimaTsun...lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:OharaNobuyaNlld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:SatoShuichiro...lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:MatsushitaHir...lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:WadaHisashiHlld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:MiyamuraTakak...lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:ChayamaKosuke...lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:IshidaToshiak...lld:pubmed
pubmed-article:19006261pubmed:authorpubmed-author:NakamuraYurik...lld:pubmed
pubmed-article:19006261pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19006261pubmed:volume8lld:pubmed
pubmed-article:19006261pubmed:ownerNLMlld:pubmed
pubmed-article:19006261pubmed:authorsCompleteYlld:pubmed
pubmed-article:19006261pubmed:pagination15lld:pubmed
pubmed-article:19006261pubmed:dateRevised2010-12-15lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:meshHeadingpubmed-meshheading:19006261...lld:pubmed
pubmed-article:19006261pubmed:year2008lld:pubmed
pubmed-article:19006261pubmed:articleTitleIdentification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity.lld:pubmed
pubmed-article:19006261pubmed:affiliationDepartment of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.lld:pubmed
pubmed-article:19006261pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19006261pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19006261lld:entrezgene
lhgdn:association:53425lhgdn:found_inpubmed-article:19006261lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19006261lld:pubmed